Multiple Gastrointestinal Cancers in the Czech Republic 1976–2005
Authors:
E. Geryk 1; P. Dítě 1; J. Kozel 2; R. Štampach 2; P. Kubíček 2
Authors‘ workplace:
Fakultní nemocnice, Brno
1; Geografický ústav Přírodovědecké fakulty MU, Brno
2
Published in:
Gastroent Hepatol 2010; 64(1): 12-21
Category:
Original Article
Overview
The aim of the study:
To describe multiple gastrointestinal cancers during 1976–2005.
Material and methods:
Czech Cancer Registry recorded 355,624 of gastrointestinal (GI) cancers, of which there were analysed primary and subsequent neoplasms by sites ICD-10: C15-C25 and C00-D48 in men and women.
Results:
Total of 41,534 multiple cancers (56.6 % men, 43.4 % women) represented 12.1 % of all registered GI cancers in men and 11.1 % in women. The primary 14,744 (35.5 %) GI cancers followed 16,362 neoplasms, the subsequent 26,790 (64.5 %) GI cancers preceded 31,519 neoplasms. The most frequent were multiple cancers of colon, rectosigmoideum and stomach, the higher were the subsequent cancers of pancreas. The number of primary GI cancers increased till 1997, then decreased, of subsequent ones increased permanently. The most percentage cancers contributed the age groups 50-69 years in men and the age up to 49 years and more than 80 years in women. The average lenght between the primary and subsequent diseases was 6.1 years. The proportion of 31.2 % synchronous and 68.8 % metachronous cancers was 1:3.6 in men and 1:5 in women. The most frequent of 5,101 synchronous were cancers of other GI 43.6 %, urinary tract 13.7 %, male genital organs 11.8 % and respiratory tract 10.8 % in men and cancers of other GI 44.2 %, female genital organs 13.8 %, urinary tract 9.8 % and breast 8.1 % in women. GI cancers of the second diagnose sequence preceded the most frequent cancers of skin 38.1 %, cancers of other GI 20.3 %, male genital organs 9.7 %, urinary 9.4 % and respiratory tract 8.2 % in men and cancers of skin 31.9 %, female genital organs 18.5 %, cancers of other GI 15.7 % and breast 15.4 % in women. From 14,744 primary GI cancers died 11,433 (77.5 %) and survived 3,311 (22.5 %) cases, from 26,790 subsequent GI cancers died 23,098 (86.2 %) and survived 3,692 (13.8 %) cases up to October 2007.
Conclusions:
From nearly 1.5 million of all neoplasm sites in the Czech registry there were every the fifth GI cancer associated with multiple neoplasm during 1976–2005.
Key words:
prevalence – primary and subsequent diseases – synchronous and metachronous occurrence – multiple cancers
Sources
1. Mackay J, Jemal A, Lee NC et al. The Cancer Atlas. Amer Cancer Society; 2006: 82, ISBN: 0-944235-62-X.
2. Konečný K, Geryk E, Kubíček P et al. Prevalence nádorů v ČR 1989-2005-2015. PřF
MU Brno 2008; 69.
3. Geryk E, Bendová M, Kubíček P et al. Vícečetné zhoubné novotvary – ukazatel zdraví a nákladů péče v onkologii. Zdravotnictví v ČR 2008; 2(11):50–55.
4. Mysliwiec PA, Cronin KA, Schatzkin A. New malignancies following cancer of the colon, rectum and anus. In: Curtis, R.E. et al. New malignancies among cancer survivors: SEER cancer registries, 1973-2000. NCI, NIH Publ. No.05-5302, Bethesda 2006: 3.
5. Stolzenberg-Solomon RZ, Fraumeni JF jr., Wideroff L et al. New malignancies following cancer of the digestive tract, excluding colorectal cancer. In: Curtis, R.E. et al.: New malignancies among cancer survivors: SEER cancer registries 1973-2000. NCI, NIH Publ. No.05-5302, Bethesda, 2006; p. 59.
6. Hoar SK, Wilson J, Blot WJ et al. Second cancer following cancer of the digestive system in Connecticut, 1935-82. Natl Cancer Inst Monogr 1985; 68: 49–82.
7. Lynge E, Jensen OM, Carstensen B. Second cancer following cancer of the digestive system in Denmark 1943-80. Natl Cancer Inst Monogr 1985; 68: 277–308.
8. Teppo L, Pukkala E, Saxen E. Multiple cancer – an epidemiologic exercise in Finland. J Natl Canc Inst 1985; 75(2): 207–217.
9. Levi F, Randimbison L, Te VC et al. Multiple primary cancers in the Vaud Cancer Registry, Switzerland 1974-89. Br J Cancer 1993; 67(2): 391–395.
10. McCredie M, Macfarlane GJ, Bell J et al. Second primary cancers after cancers of the colon and rectum in New South Wales, Australia 1972-91. Canc Epidemiol Biomarkers Prev 1997; 6(3): 155–160.
11. Evans HS, Moller H, Robinson D et al. The risk of subsequent primary cancers after colorectal cancer in southeast England. Gut 2002; 50(5): 647–652.
12. Vítová V, Pecen L. Kolorektální karcinomu jako nádorová duplicita. In: Vyzula R et al. Rakovina tlustého střeva a konečníku-vybrané kapitoly. 2008: 55–61. ISBN 978-86-7345-140-0.
13. ÚZIS: Národní onkologický registr – pokyny k obsahu datové struktury. Závazné pokyny NZIS, verze 051-20060101/2, ÚZIS ČR, 2005: 46.
14. Geryk E, Dítě P, Pešek M et al. Následné primární novotvary u 125 262 onkologicky nemocných v ČR 1976-2005. Onkologie 2009; 3(3): 181–189.
15. Barták M, Horáková P. K současným reformám zdravotnictví v USA. Zdravotnictví v České Republice 2009; 2(12): 60–62.
16. Geryk E, Dítě P, Kozel J et al. Vícečetné novotvary u nemocných s karcinomy žaludku v ČR 1976–2005. Gastroenterologie 2010, v tisku.
17. Stampach R, Konecny M, Kubicek P et al. Dynamic cartographic methods for visualisation of health statistics. Proceedings ICA Symposium on Cartography for Central and Eastern Europe,Vinna, Vienna Univ of Technology 2009; 867–878.
18. Kubíček P, Geryk E, Štampach R et al. Geografické rozložení vícečetných novotvarů v České republice 1976-2005. 2010, ISBN 978-80-903255-3-1, v tisku.
19. Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am 2002;11(2): 235–256.
20. Engel LS, Chow WH, Vaughan TL et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 2003; 95(18): 1404–1413.
21. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349(23): 2241–2252.
22. Graziano F, Humar B, Guilford P. The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice. Ann Oncol 2003; 14(12): 1705–1713.
23. El-Omar EM, Rabkin CS, Gammond MD et al. Increased risk of noncardia gastric cancer associated with proinflamatory cytokine gene polymorphisms. Gastroenterology 2003; 124(5): 1193–1201.
24. Neugut AI, Jacobson JS, Suh S et al. The epidemiology of cancer of the small bowel. Canc Epidem Biomarkers Prev 1998; 7(3): 243–251.
25. Delaunoit T, Neczyporenko F, Limburg PJ et al. Pathogenesis and risk factors of small bowel adenocarcinoma: a colorectal cancer sibling? Am J Gastroenterol 2005; 100(3): 703–710.
26. Samanic C, Gridley G, Chow WH et al. Obesity and cancer risk among white and black United States veterans. Canc Causes Control 2004; 15(1): 35–43.
27. Kaerlev L, Teglbjaerg PS, Sabroe S et al. Is there an association between alcohol intake or smoking and small bowel adenocarcinoma? Results from European multi-center case-control study. Canc Causes Control 2000; 11(9): 791–797.
28. Martinez ME. Primary prevention of colorectal cancer: lifestyle, nutrition, exercise. Recent Results Canc Res 2005; 166: 177–211.
29. Cho E, Smith-Warner SA, Ritz J et al. Alcohol intake and colorectal cancer: a pooled analysis of 8 cohort studies. Ann Intern Med 2004; 140(8): 603–613.
30. Corrao G, Bagnardi V, Zambon A et al. A meta-analysis of alcohol consumption and the risk of 15 diseases. Prev Med 2004; 38(5): 613–619.
31. Giovannucci E. An updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer. Canc Epidem Biomarkers Prev 2001; 10(7): 725-731.
32. Ekbom A, Helmick C, Zack M et al. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990; 323(18): 1228–1233.
33. Ekbom A, Helmick C, Zack M et al. Increased risk of large-bowel cancer in Crohn´s disease with colonic involvement. Lancet 1990; 336(8711): 357–359.
34. Burt RW, DiSario JA, Cannon-Albright L. Genetics of colon cancer: impact of inheritance on colon cancer risk. Ann Rev Med 1995; 46: 371–379.
35. Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet 1999; 36(11): 801–818.
36. Burt RW. Colon cancer screening. Gastroenterology 2000; 119(3): 837–853.
37. Potter JD. Colorectal cancer: molecules and populations. J Natl Canc Inst 1999; 91(11): 916–932.
38. Schiffman M, Kjaer SK. Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Canc Inst Monogr 2003; 31: 14–19.
39. Palefsky JM, Holly EA. Immunosuppression and co-infection with HIV. J Natl Canc Inst Monogr 2003; 31: 41–46.
40. Birkeland SA, Storm HH, Lamm LU et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Canc 1995; 60(2): 183–189.
41. Valea FA. Liver and hepatic duct cancer. Clin Obstet Gynecol 2002; 45(3): 939-951.
42. El-Serag HB. Hepatocelular carcinoma: recent trends in the United States. Gastroenterology 2004; 127(5 Suppl 1): S27–S34.
43. Misra S, Chaturvedi A, Misra NC et al. Carcinoma of the gallbladder. Lancet Oncol 2003; 4(3): 167–176.
44. Cullen S, Chapman R. Primary sclerosing cholangitis. Autoimun Rev 2003; 2(6): 305–312.
45. Lazcano-Ponce EC, Miquel JF, Munoz N et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 2001; 51(6): 349–364.
46. Lillemoe KD. Tumors of the gallbladder, bile ducts and ampulla. Semin Gastrointest Dis 2003; 14(4): 208–221.
47. van Leeuwen FE, Travis LB. Second cancers. In: DeVita, V.T. jr. et al. Cancer: Principles and practice of oncology. 7th ed. Philadelphia, Lippincott Williams-Wilkins, 2005: 2575–2602.
48. Geryk E, Dítě P, Sedláková L et al. Trend vícečetných nemelanomových nádorů kůž z pohledu jejich epidemiologie. Dermatologie pro praxi, 2010; 1(4), v tisku.
49. Petruželka L. Od onkologického nihilismu k aktivní léčbě pokročilých nádorových onemocnění. Sborník XIII. dny prof. V.Staška, Praha 2009;4–5, ISBN 978-80-254-1284-8.
50. ÚZIS: Novotvary ČR 2005. ÚZIS ČR, 2008:254, ISBN 978-80-7280-723-9.
Labels
Paediatric gastroenterology Gastroenterology and hepatology SurgeryArticle was published in
Gastroenterology and Hepatology
2010 Issue 1
Most read in this issue
- The Diagnosis and Treatment of Globus Pharyngeus
- Recommendation for Vaccinations in Patients with Crohn’s Disease and Ulcerative Colitis on Immunosuppressive and/or Biological Therapy
- Neuroendocrine Tumors of the Large Bowel
- Enteropathy-Associated Non-Hodgkin T-Lymphoma as a Complication of Late Diagnosis of Celiac Disease in a Geriatric Patient